Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Non-Current Deferred Tax Liability: 2018-2025

  • Dr Reddys Laboratories' Non-Current Deferred Tax Liability rose 1400.00% to $165.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $165.0 million, marking a year-over-year increase of 1400.00%. This contributed to the annual value of $165.0 million for FY2025, which is 1400.00% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Non-Current Deferred Tax Liability stood at $165.0 million for Q1 2025, which was up 1,400.00% from $11.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' 5-year Non-Current Deferred Tax Liability high stood at $165.0 million for Q1 2025, and its period low was $1.0 million during Q1 2022.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $11.0 million (2024), whereas its average is $62.0 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first plummeted by 80.00% in 2022, then soared by 1,400.00% in 2025.
  • Dr Reddys Laboratories' Non-Current Deferred Tax Liability (Quarterly) stood at $5.0 million in 2021, then slumped by 80.00% to $1.0 million in 2022, then skyrocketed by 900.00% to $10.0 million in 2023, then climbed by 10.00% to $11.0 million in 2024, then surged by 1,400.00% to $165.0 million in 2025.
  • Its last three reported values are $165.0 million in Q1 2025, $11.0 million for Q1 2024, and $10.0 million during Q1 2023.